...
首页> 外文期刊>Pancreas >Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop
【24h】

Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

机译:21世纪的慢性胰腺炎-研究挑战与机遇:美国国立糖尿病与消化及肾脏疾病研究所工作坊摘要

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities in chronic pancreatitis (CP) and its sequelae. This conference marked the 20th year anniversary of the discovery of the cationic trypsinogen (PRSS1) gene mutation for hereditary pancreatitis. The event was held on July 27, 2016, and structured into 4 sessions: (1) pathophysiology, (2) exocrine complications, (3) endocrine complications, and (4) pain. The current state of knowledge was reviewed; many knowledge gaps and research needs were identified that require further investigation. Common themes included the need to design better tools to diagnose CP and its sequelae early and reliably, identify predisposing risk factors for disease progression, develop standardized protocols to distinguish type 3c diabetes mellitus from other types of diabetes, and design effective therapeutic strategies through novel cell culture technologies, animal models mimicking human disease, and pain management tools. Gene therapy and cystic fibrosis conductance regulator potentiators as possible treatments of CP were discussed. Importantly, the need for CP end points and intermediate targets for future drug trials was emphasized.
机译:国立糖尿病与消化及肾脏疾病研究所赞助了一个研讨会,重点研究慢性胰腺炎(CP)及其后遗症的研究空白和机会。这次会议标志着遗传性胰腺炎的阳离子胰蛋白酶原(PRSS1)基因突变的发现20周年。该活动于2016年7月27日举行,分为4节:(1)病理生理学,(2)外分泌并发症,(3)内分泌并发症和(4)疼痛。审查了目前的知识状况;确定了许多知识差距和研究需求,需要进一步调查。共同的主题包括需要设计更好的工具来及早和可靠地诊断CP及其后遗症,确定疾病进展的诱发危险因素,制定标准化的方案以区分3c型糖尿病和其他类型的糖尿病,以及通过新型细胞设计有效的治疗策略文化技术,模仿人类疾病的动物模型以及疼痛管理工具。讨论了基因治疗和囊性纤维化传导调节剂作为CP的可能治疗方法。重要的是,强调了对CP终点和未来药物试验中间目标的需求。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号